Article Information
History
- July 24, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Maria C Schneeweiss, MD1,2,*,
- Sandra Leonard, MPH3,
- Andrew Weckstein4,
- Sebastian Schneeweiss, MD, ScD1,2 and
- Jeremy A Rassen, ScD4
- 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, and Department of Dermatology Brigham and Women’s Hospital, Boston, MA
- 2Harvard Medical School, Boston, MA
- 3HealthVerity, Inc
- 4Aetion, Inc
- ↵*Correspondence to: Maria Schneeweiss, MD, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, 1 Brigham Circle, suite 3030, Boston, MA 02120; Phone: 617 278-0930, Email: mschneeweiss{at}bwh.harvard.edu
Posted July 24, 2020.
Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US
